Drug
GSK221149A clinical trials
Also written Retosiban and GSK221149A.
- studies test it
- 10
- open now
- 0
- in phase 3
- 3
- first study started
- 2006
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
10 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 3 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 1
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Ketoconazole (1) · EFZ 600 (1)
Studies
Open first, then newest update. How each study uses GSK221149A is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm LabourTerminatedPhase 3GlaxoSmithKlineNCT02292771Written as Retosiban
- A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm LaborTerminatedPhase 3GlaxoSmithKlineNCT02377466Written as Retosiban IV infusion
- Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment StudiesCompletedPhase 3GlaxoSmithKlineNCT02292784Written as Retosiban
- The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term LaborCompletedPhase 2GlaxoSmithKlineNCT00404768Written as GSK221149A
- A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With KetoconazoleCompletedPhase 1GlaxoSmithKlineNCT01627587Written as GSK221149 750 mg
- This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.CompletedPhase 1GlaxoSmithKlineNCT01702376Written as Retosiban 100 mg
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)CompletedPhase 1GlaxoSmithKlineNCT01867996Written as Retosiban
- Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese WomenCompletedPhase 1GlaxoSmithKlineNCT02377414Written as Retosiban solution for Infusion
- Absorption, Distribution, Metabolism And Excretion Study For GSK221149ACompletedPhase 1GlaxoSmithKlineNCT00457925Written as GSK221149A
- A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult SubjectsTerminatedPhase 1GlaxoSmithKlineNCT00449709Written as GSK221149